Drugs Made In America Acquisition II Corp. (DMIIU) Cash & Equivalents (2024 - 2025)

Drugs Made In America Acquisition (DMIIU) has reported Cash & Equivalents for 2 consecutive years, with $223.0 the latest figure, recorded in Q4 2025.

• In Q4 2025, Cash & Equivalents fell 98.69% year-over-year to $223.0; the TTM figure through Dec 2025 stood at $223.0 (down 98.69% YoY), while the FY2025 annual figure was $223.0, down 98.69% from the prior year.
• Cash & Equivalents slipped to $223.0 in Q4 2025 per DMIIU's latest filing, from $315087.0 in the prior quarter.
• Across five years, Cash & Equivalents topped out at $315087.0 in Q3 2025 and bottomed at $223.0 in Q4 2025.